Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
British Journal of Cancer
|
June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
C Pezaro, D Mukherji, N Tunariu, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 16, 2011
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer
Gerhardt Attard, Alison H M Reid, Richard J Auchus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2009
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors
Alison H M Reid, Andrew Protheroe, Gerhardt Attard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L R Molife, G Attard, P C Fong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 10, 2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
J Mezynski, C Pezaro, D Bianchini, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 31, 2012
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
Alison H M Reid, Gerhardt Attard, Daniel Brewer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
British Journal of Cancer
|
March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
S P Blagden, L R Molife, A Seebaran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, H-T Arkenau, J E Ang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Gerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
British Journal of Cancer
|
June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
C Pezaro, D Mukherji, N Tunariu, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 16, 2011
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer
Gerhardt Attard, Alison H M Reid, Richard J Auchus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2009
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors
Alison H M Reid, Andrew Protheroe, Gerhardt Attard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L R Molife, G Attard, P C Fong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 10, 2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
J Mezynski, C Pezaro, D Bianchini, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 31, 2012
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
Alison H M Reid, Gerhardt Attard, Daniel Brewer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
British Journal of Cancer
|
March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
S P Blagden, L R Molife, A Seebaran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2008
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D Olmos, H-T Arkenau, J E Ang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Gerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
Page
of 5